Investigating the Acute Effects of Increasing Glucagon Exposure in Healthy Participants
Investigating the Effect of Glucagon on Cognitive Function and Cerebral Glucose Metabolism in Humans: A Pilot Study
In this study the investigators will investigate the acute effects of increasing glucagon exposure on metabolic parameters in healthy participants.
Participants will participate in one study day. After initial baseline blood samples, a three-hour intravenous infusion with glucagon will be initiated. The infusion rate will be increased every 30 minutes.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Ten participants with normal health will be included, and each participant will participate in one study day.
Participants will arrive after an overnight fast and will be placed in a hospital bed in a semi-recumbent position. In each antecubital vein an intravenous catheter will be placed; one for administration of glucagon and one for blood sampling.
Two baseline blood samples will be drawn before the glucagon infusion is started. The glucagon infusion rate will be increased every 30 minutes (infusion rates are 0,01 ng/kg/min, 0,1 ng/kg/min, 0,5 ng/kg/min, 1,0 ng/kg/min, 10 ng/kg/min and 50 ng/kg/min).
Blood samples for the analysis of plasma glucagon, glucose, insulin, C-peptide etc. will be drawn every 15 minutes.
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Nina Hansen, MD
- Phone Number: 0045 21205944
- Email: nina.lerberg.hansen.01@regionh.dk
Study Contact Backup
- Name: Sasha Alexander S Kjeldsen, MSc PhD
- Email: sasha.alexandra.sampson-ceutz@regionh.dk
Study Locations
-
-
-
Copenhagen, Denmark, 2400
- Department of Clinical Biochemistry, Copenhagen University Hospital - Bispebjerg and Frederiksberg, Copenhagen, Denmark
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Capable of understanding the participant information and signing the consent form
- Between 25 and 70 years of age at the time of screening
- Body mass index (BMI) ≤ 25 kg/m2 at the time of screening
Exclusion Criteria:
- Enrolment in other research projects that might interfere with the study
- Diabetes diagnosis (type 1 and 2)
- Pregnancy or breastfeeding
- Use of medications which, in the opinion of the investigator, may jeopardise participant's safety or compliance with the protocol
- Impaired liver function defined as either alanine aminotransferase (ALAT) and/or aspartate aminotransferase (ASAT) ≥ 2 times normal values
- Kidney disease defined as serum creatinine levels ≥ 126 μmol/L for male and ≥ 111 μmol/L for female
- Inadequately treated blood pressure at screening defined as repeated resting blood pressure outside the range 90-150 mmHg for systolic and 50-100 mmHg for diastolic
- Active or recent malignant disease
- Current or history of severe alcohol use or drug/chemical abuse as per investigator's judgement
- Any chronic disorders or severe diseases which, in the opinion of the investigator, might jeopardise participant's safety or compliance with the protocol
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Glucagon Infusion
|
A three-hour intravenous infusion with glucagon with increasing infusion rate (from 0,01 ng/kg/min up to 50 ng/kg/min)
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Glucagon infusion rate that increases plasma glucose
Time Frame: 0-180 minutes
|
Glucagon infusion rate at which plasma glucose levels are significantly increased compared to baseline
|
0-180 minutes
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Glucagon infusion rate that increases plasma cAMP
Time Frame: 0-180 minutes
|
Glucagon infusion rate at which plasma cAMP levels are significantly increased compared to baseline
|
0-180 minutes
|
|
Glucagon infusion rate that decreases plasma amino acids
Time Frame: 0-180 minutes
|
Glucagon infusion rate at which plasma amino acid levels are significantly decreased compared to baseline
|
0-180 minutes
|
|
Glucagon infusion rate that affects plasma triglycerides
Time Frame: 0-180 minutes
|
Glucagon infusion rate at which plasma triglycerides are significantly changed compared to baseline
|
0-180 minutes
|
|
Glucagon infusion rate that affects plasma nonesterified fatty acids
Time Frame: 0-180 minutes
|
Glucagon infusion rate at which plasma nonesterified fatty acids are significantly changed compared to baseline
|
0-180 minutes
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Nicolai J Wewer Albrecthsen, MD PhD, Department of Clinical Biochemistry, Copenhagen University Hospital - Bispebjerg and Frederiksberg Hospital, Copenhagen, Denmark
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- GluCoMet_stepwise glucagon
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.